Adult: As 0.05% cream or ointment: Apply thinly onto the affected area(s) bid or tid. Discontinue therapy once control is achieved. If no improvement is seen within 2 weeks, diagnosis reassessment may be needed. Child: ≥1 year As 0.05% cream or ointment: Same as adult dose. Discontinue therapy once control is achieved. If no improvement is seen within 2 weeks, diagnosis reassessment may be needed.
Contraindications
Acne, rosacea, perioral dermatitis; bacterial or fungal skin infections; tuberculous and viral (especially herpes simplex, vaccinia, or varicella) skin lesions.
Special Precautions
Not recommended for the treatment of diaper dermatitis. Children. Pregnancy and lactation.
Adverse Reactions
Significant: Hypercortisolism or HPA axis suppression (particularly in younger children or at high doses for prolonged periods); allergic contact dermatitis, local sensitisation (e.g. redness, irritation); bacterial or fungal superinfection (prolonged use); Kaposi's sarcoma (prolonged use); systemic effects (e.g. manifestations of Cushing's syndrome, hyperglycaemia, glycosuria); intracranial hypertension and growth retardation (prolonged use in children). Skin and subcutaneous tissue disorders: Itching, burning sensation, dryness, papular rashes; folliculitis, acneiform eruptions, hypertrichosis, hypopigmentation, perioral dermatitis, miliaria, skin atrophy, striae (particularly when used with occlusive dressing).
Avoid contact with the eyes. Do not use occlusive dressings unless directed by the doctor.
Monitoring Parameters
Monitor growth (particularly in children); ACTH stimulation test, morning plasma cortisol test, and urinary free cortisol test (if HPA axis suppression is suspected). Assess for signs and symptoms of HPA axis suppression/adrenal insufficiency and bacterial or fungal skin infection.
Overdosage
Symptoms: Secondary adrenal insufficiency and manifestations of hypercortisolism, including Cushing's disease (particularly for long-term or excessive use). Management: Symptomatic treatment. Treat electrolyte imbalance as necessary. In case of chronic toxicity, slowly withdraw alclometasone.
Action
Description: Mechanism of Action: Alclometasone is a synthetic topical corticosteroid that has anti-inflammatory, antipruritic, and vasoconstrictive properties. It induces phospholipase A2 inhibitory proteins (lipocortins) and sequentially inhibits the release of arachidonic acid, thereby depressing the formation, release, and action of endogenous inflammatory mediators (e.g. kinins, histamine, liposomal enzymes, prostaglandins). Alclometasone has a low to moderate range of potency. Pharmacokinetics: Absorption: Absorbed systemically (approx 3%) after 8 hours when applied to intact skin. Excretion: Via urine and faeces.
Chemical Structure
Alclometasone Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 5311000, Alclometasone. https://pubchem.ncbi.nlm.nih.gov/compound/Alclometasone. Accessed Apr. 25, 2024.
Storage
Store between 2-30°C. Storage recommendations may vary among individual products or between countries (refer to detailed product guidelines).
Sign Out
Continue with Google